Article
BRCA Testing in Asian Patients with Ovarian Cancer: Standard Clinical Practice or Mutation Prediction Model?
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jul 2026
Ang Boon Hong, Yoon Sook-Yee, Lim Joanna, Hassan Nur Tiara, Tai Mei-Chee, Wong Zhi Lei, Chow Jo Yi, Lee Xin Wen, Thong Meow-Keong, Ch'ng Gaik-Siew, Omar Jamil, Yong Chee-Meng, Aliyas Ismail, Abdul Malik Rozita, Subramaniam Suguna, Sim Wee-Wee, Lim Chun Sen, Lee Saw-Joo, Lim Keng-Joo, Shafiee Mohamad Nasir, Ismail Fuad, Ismail Mohd Pazudin, Kumarasamy Suresh, Low John Seng Hooi, Ahmad Mustafa Ahmad Muzamir, Makanjang Mary J, Tayib Shahila, Cheah Nellie L C, Fong Chee-Kin, Ho Kean-Fatt, Deniel Azura, Ang Soo-Fan, Ahmad Badruddin Ahmad Radzi, Tho Lye-Mun, Woo Yin Ling, Ho Weang-Kee, Teo Soo-Hwang
Abstract excerpt
BACKGROUND: Germline BRCA1/2 testing is recommended for all patients with ovarian cancer, as identifying pathogenic variants (PV) informs treatment and enables family cascade testing. However, in resource-limited settings, high testing costs often limit feasibility. An alternative approach is to use predictive models to prioritize patients at risk, optimizing resource allocation. Existing models are largely...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
